Nextblockbuster,

Those benefits you listed are just the general benefits of having any abstract accepted for presentation at AHA. However, BETonMACE is not just any old abstract. There are hundreds if not over a thousand normal abstracts at AHA.

BETonMACE is only one of a handful of abstracts designated as late breaking science. Here are some details and background on the format of the AHA late breaker session that Dr. Kausik Ray will give Saturday November 16.

There are only 6 Late Breaking Science sessions with 3-5 presentations per session. These will be highly attended and highly covered by media. You can see the whole list at the link below.

https://professional.heart.org/professional/EducationMeetings/MeetingsLiveCME/ScientificSessions/UCM_442723_Late-Breaking-Science-Scientific-Sessions.jsp

Here are some guidelines specific to the late breaking science presentations:

2019 Late-Breaking Science Guidelines (PDF)

Guidelines for Late-Breaking Science Presentations. Late-Breaking Science sessions are innovative and provide the latest breakthroughs in clinical science. These sessions provide notable exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field.

Embargoed Media Briefing: Late-Breaking Science will be considered for embargoed media briefings or other news activities, where select principal investigators or their representatives will discuss the results of their studies and answer questions with members of the media. Times may vary slightly.

Investigator Meetings: The only exceptions to the above-mentioned embargo policy is closed investigator meetings for participants in the trial. Such investigator dinners or meetings in which trial results will be discussed should be held the evening before their scheduled presentation after 7 p.m. Central Time to avoid unintended public disclosure of trial results. Graphics (slide or print) that contain key trial results should be kept to a minimum and not distributed. Media or other outside parties may not be invited to these events.

Simultaneous Journal Publication of Clinical Trials: Simultaneous publication of Clinical Trials is acceptable and encouraged as long as the embargo policies of the AHA and the involved journals are coordinated. If a clinical trial has been submitted to and accepted for publication, the presenter is responsible for ensuring that the journal editor respects the AHA publication embargo policy. Publication of a clinical trial either in print or on a journal web site prior to presentation at Sessions will necessitate withdrawal of the trial from the program.

BearDownAZ